Dianne C. Whitfield sold $1.3M of TARS
Chief Human Resources Officer at Tarsus Pharmaceuticals, Inc.. 15,565 shares at an average of $80.67, traded Jan 2, 2026, filed Jan 6, 2026.
Score components
- +15RoleOfficer
- +25Trade size$1.3M at market
- +10Share of holdings soldSold 40% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -22.4%, 3m -13.9%, 6m -11.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001839516-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 2, 2026 | SOpen-market sale Common Stock10b5-1 | -5,715 | $80.09 | $458k | 33,243 | Jan 6, 2026 |
| Jan 2, 2026 | SOpen-market sale Common Stock10b5-1 | -8,122 | $80.71 | $656k | 25,121 | Jan 6, 2026 |
| Jan 2, 2026 | SOpen-market sale Common Stock10b5-1 | -835 | $81.90 | $68k | 24,286 | Jan 6, 2026 |
| Jan 2, 2026 | SOpen-market sale Common Stock10b5-1 | -893 | $82.93 | $74k | 23,393 | Jan 6, 2026 |
Related signals
Other insiders at Tarsus Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Tarsus Pharmaceuticals, Inc. | William J Link Phd director | $980k 12,500 shares | -12% | |
| 44Moderate | Tarsus Pharmaceuticals, Inc. | Bobak R. Azamian President/CEO and Board Chair | $906k 10,000 shares | -1% | |
| 55Moderate | Tarsus Pharmaceuticals, Inc. | Elizabeth Yeu Lin Chief Medical Officer | $1.2M 13,953 shares | -105% | |
| 31Weak | Tarsus Pharmaceuticals, Inc. | Seshadri Neervannan Chief Operating Officer | $388k 4,564 shares | -5% | |
| 42Moderate | Tarsus Pharmaceuticals, Inc. | Bobak R. Azamian President/CEO and Board Chair | $801k 10,000 shares | -1% | |
| 44Moderate | Tarsus Pharmaceuticals, Inc. | Elizabeth Yeu Lin Chief Medical Officer | $898k 11,578 shares | -50% | |
| 40Moderate | Tarsus Pharmaceuticals, Inc. | Bobak R. Azamian President/CEO and Board Chair | $615k 10,000 shares | -1% | |
| 43Moderate | Tarsus Pharmaceuticals, Inc. | Jeffrey S Farrow See Remarks | $877k 14,396 shares | -20% | |
| 42Moderate | Tarsus Pharmaceuticals, Inc. | Katherine Goodrich director | $183k 2,954 shares | -57% | |
| 37Weak | Tarsus Pharmaceuticals, Inc. | William J Link Phd director | $776k 12,500 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.